Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3313231 | 0.87 | CYP3A4 (0.42) | CYP3A4MAPK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2362967 | 0.85 | CYP3A4 (0.50) | CYP3A4MAPK1SMN1; SMN2ALPLPOLB | |
| SCHEMBL2352735 | 0.84 | CYP3A4 (0.45) | CYP3A4ALPL | |
| SCHEMBL3313139 | 0.83 | CYP3A4 (0.45) | CYP3A4MAPK1SMN1; SMN2ALPLMAPT | |
| SCHEMBL3312658 | 0.83 | CYP3A4 (0.44) | CYP3A4MAPK1ALPLPOLBMAPT | |
| SCHEMBL2362843 | 0.78 | CYP3A4 (0.48) | CYP3A4TP53ALPLLMNA | |
| SCHEMBL2348091 | 0.78 | CYP3A4 (0.51) | CYP3A4MAPK1TP53MEN1KMT2A | |
| SCHEMBL3308176 | 0.77 | CYP3A4 (0.42) | CYP3A4TP53MEN1KMT2APOLB | |
| SCHEMBL2363082 | 0.77 | HTR2A (0.44) | CYP3A4TP53ALPLLMNA | |
| SCHEMBL2363467 | 0.77 | CYP3A4 (0.43) | CYP3A4TP53MEN1KMT2AALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232271-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-07-31 | — | — | US | claimed |
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC | 2010-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100111900-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | POLR2A, EIF2AK2, POLR2B | CYP3A4 423/4885MAPK1 2485/4885TP53 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.